Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding
Graphical abstract
Section snippets
Acknowledgments
The authors would like to thank Ms. Nancy Tsou for growing diffractable crystals of 1, Dr. Rodney Bednar, Ms. Wei Lemaire, and Mr. Joe Bruno for determining binding potencies of key compounds, and Dr. Charles Ross and Ms. Joan Murphy for high resolution mass spectral analyses.
References and notes (24)
- et al.
Bull. Mater. Sci.
(2005) - et al.
J. Mol. Struct.
(2002) - et al.
J. Med. Chem.
(2002) - et al.
J. Am. Chem. Soc.
(2004)et al.J. Am. Chem. Soc.
(2005) - et al.
Curr. Opin. Drug. Dis. Dev.
(2006)et al.Curr. Top. Med. Chem.
(2008)et al.Chimia
(2008)et al.J. Med. Chem.
(2009) - (a)Whitman, D. B.; Cox, C. D.; Breslin, M. J.; Brashear, K. M.; Schreier, J. D.; Bogusky, M. J.; Bednar, R. A.;...(b)These analogs were first disclosed in: Brashear, K. M; Coleman, P. J.; Cox, C. D.; Smith, A. M.; Whitman, D. B. PCT...(c)Some of these results were disclosed in a recent poster presentation: Breslin, M. J.; Cox, C. D.; Whitman, D. B.;...
- et al.
Magn. Reson. Chem.
(1987) - et al.
J. Biol. Chem.
(1998)
Angew. Chem., Int. Ed.
Cited by (52)
Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia
2020, Bioorganic and Medicinal ChemistryCitation Excerpt :In addition, the metabolic stability in human liver microsomes (hMS) and the efflux ratio (ER) of P-glycoprotein (P-gp) were evaluated for each compound. Also, the LogD7.4 value of each compound was assessed using high-performance liquid chromatography (LogDHPLC) as an indicator of lipophilicity.22 As stated in the Introduction, we have been focusing on the development of a potent and orally bioavailable DORA that possesses an optimal PK profile, including rapid absorption and a favorable short half-life.
Molecular modeling technology studies of novel pyrazoylethylbenzamide derivatives as selective orexin receptor 1 antagonists
2019, Journal of the Taiwan Institute of Chemical EngineersCitation Excerpt :Fig. 11(B) and (D) was corresponding 2D non-bonded interaction maps. Compound 33, like Suvorexant, accepts a horseshoe-like conformation in both pockets [46]. In the OX2R pocket, there was an F-shaped π–π stacking between fluorobenzene ring and tetrazole ring.
Methyl-containing pharmaceuticals: Methylation in drug design
2018, Bioorganic and Medicinal Chemistry LettersMeasurement, Interpretation and Use of Free Ligand Solution Conformations in Drug Discovery
2016, Progress in Medicinal Chemistry